Cargando…

An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor

BACKGROUND: Our study aimed to build a risk stratification system predicting the progression-free survival (PFS) to classify patients into diverse prognostic subgroups for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor. METHODS: 404 patients from our center were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Zegui, Yu, Yang, Tian, Tian, Li, Caili, Luo, Jieyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543541/
https://www.ncbi.nlm.nih.gov/pubmed/37790972
http://dx.doi.org/10.1016/j.heliyon.2023.e20465
_version_ 1785114317269499904
author Tu, Zegui
Yu, Yang
Tian, Tian
Li, Caili
Luo, Jieyan
author_facet Tu, Zegui
Yu, Yang
Tian, Tian
Li, Caili
Luo, Jieyan
author_sort Tu, Zegui
collection PubMed
description BACKGROUND: Our study aimed to build a risk stratification system predicting the progression-free survival (PFS) to classify patients into diverse prognostic subgroups for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor. METHODS: 404 patients from our center were enrolled in this study and 70% patients (n = 282) were randomly assigned into the training cohort and other 30% patients (n = 122) into the validation cohort. A testing cohort contained 81 patients from other centers were used to assess the generalizability of model. Cox regression analyses were used to identify the most significant clinical parameters. The model's performance was assessed by using concordance index (C-index), calibration curves, Decision Curve Analyses (DCAs), net reclassification improvement (NRI), integrated discrimination improvement (IDI) analyses, and survival curve. RESULTS: Five clinical parameters were identified as the most significant predictors by using cox regression. We then integrated them into a Nomogram to Evaluate the relative PFS of ICIs Treatment (NEPIT). The C-index of NEPIT in the training cohort, the validation cohort and testing cohort was 0.789 (95%CI: 0.750–0.828), 0.745 (95%CI: 0.706–0.784), and 0.766 (95%CI: 0.744–0.788), respectively. The calibration curves presented a good congruence between the predictions and actual observations. The Decision Curve Analyses (DCAs) reflected positive net benefits can be obtained for NEPIT. The results from NRI and IDI analyses showed that the NEPIT could improve predictive power of TPS. In addition, the further constructed risk stratification system could effectively categorize patients into different risk subgroups. CONCLUSION: The tools developed in this study would have value in guiding the optimal patient selection for precision care.
format Online
Article
Text
id pubmed-10543541
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105435412023-10-03 An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor Tu, Zegui Yu, Yang Tian, Tian Li, Caili Luo, Jieyan Heliyon Research Article BACKGROUND: Our study aimed to build a risk stratification system predicting the progression-free survival (PFS) to classify patients into diverse prognostic subgroups for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor. METHODS: 404 patients from our center were enrolled in this study and 70% patients (n = 282) were randomly assigned into the training cohort and other 30% patients (n = 122) into the validation cohort. A testing cohort contained 81 patients from other centers were used to assess the generalizability of model. Cox regression analyses were used to identify the most significant clinical parameters. The model's performance was assessed by using concordance index (C-index), calibration curves, Decision Curve Analyses (DCAs), net reclassification improvement (NRI), integrated discrimination improvement (IDI) analyses, and survival curve. RESULTS: Five clinical parameters were identified as the most significant predictors by using cox regression. We then integrated them into a Nomogram to Evaluate the relative PFS of ICIs Treatment (NEPIT). The C-index of NEPIT in the training cohort, the validation cohort and testing cohort was 0.789 (95%CI: 0.750–0.828), 0.745 (95%CI: 0.706–0.784), and 0.766 (95%CI: 0.744–0.788), respectively. The calibration curves presented a good congruence between the predictions and actual observations. The Decision Curve Analyses (DCAs) reflected positive net benefits can be obtained for NEPIT. The results from NRI and IDI analyses showed that the NEPIT could improve predictive power of TPS. In addition, the further constructed risk stratification system could effectively categorize patients into different risk subgroups. CONCLUSION: The tools developed in this study would have value in guiding the optimal patient selection for precision care. Elsevier 2023-09-27 /pmc/articles/PMC10543541/ /pubmed/37790972 http://dx.doi.org/10.1016/j.heliyon.2023.e20465 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Tu, Zegui
Yu, Yang
Tian, Tian
Li, Caili
Luo, Jieyan
An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor
title An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor
title_full An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor
title_fullStr An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor
title_full_unstemmed An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor
title_short An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor
title_sort online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with pd-(l)1 inhibitor
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543541/
https://www.ncbi.nlm.nih.gov/pubmed/37790972
http://dx.doi.org/10.1016/j.heliyon.2023.e20465
work_keys_str_mv AT tuzegui anonlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT yuyang anonlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT tiantian anonlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT licaili anonlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT luojieyan anonlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT tuzegui onlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT yuyang onlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT tiantian onlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT licaili onlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor
AT luojieyan onlineclinicalmodelandriskstratificationsystemtopredictprogressionfreesurvivalforadvancednonsmallcelllungcancerpatientstreatedwithpdl1inhibitor